Visa stock snaps a five-day slide as Wall Street rallies; CEO share sale disclosed
6 January 2026
1 min read

Visa stock snaps a five-day slide as Wall Street rallies; CEO share sale disclosed

New York, Jan 5, 2026, 18:40 EST — After-hours

  • Visa shares rose 2.1% on Monday, ending a five-session losing streak.
  • A regulatory filing showed CEO Ryan McInerney exercised options and sold 10,485 shares under a pre-set trading plan.
  • Traders’ next focus is Friday’s U.S. jobs report, a key input for interest-rate expectations.

Visa Inc shares rose 2.1% to $353.80 on Monday, snapping a five-day losing streak. The stock was little changed after the bell. 1

The move matters because investors are starting 2026 re-pricing the outlook for consumer activity and interest rates — two swing factors for payment networks that earn fees as card spending moves across their rails. Visa’s shares have lagged their 52-week peak, leaving less room for disappointment if economic data weakens. 1

It also lands as money rotates into financial stocks from parts of mega-cap technology, with traders looking for earnings momentum ahead of the quarterly reporting season. “The mood has been favoring financial stocks in recent days,” said Steve Sosnick, chief market analyst at Interactive Brokers. 2

Broader U.S. stocks closed higher on Monday, with the Dow hitting a record and the S&P 500 up 0.64%, in a session Reuters said was lifted by financial shares and energy stocks after U.S. military action in Venezuela. 2

A filing with the U.S. Securities and Exchange Commission showed Visa Chief Executive Ryan McInerney exercised 10,485 employee stock options and sold the same number of Class A shares at $349.18 apiece. 3

The filing said the transactions were made under a Rule 10b5-1 plan — a pre-arranged trading program companies use to reduce the appearance that insiders are trading on non-public information. 3

Payments peers were mixed. Mastercard shares rose on the day, while Visa’s gain still left it below its June high of $375.51, market data showed. 1

The bounce does not erase the risk case. Payment stocks can come under pressure if signs emerge that consumers are pulling back, or if cross-border spending — tied closely to travel — cools, while fee-related scrutiny remains a recurring overhang for the industry.

Before Tuesday’s open, traders will weigh whether Monday’s bounce has follow-through amid a busy U.S. data calendar and shifting rate bets. Investors are also watching the Federal Reserve’s January 27-28 policy meeting for signals on the pace of easing in 2026. 4

The next near-term catalyst is Friday’s U.S. Employment Situation report for December, due at 8:30 a.m. ET, which can reset expectations for growth and interest rates. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
IREN Limited stock jumps 13% as bitcoin rallies — here’s what to watch next
Previous Story

IREN Limited stock jumps 13% as bitcoin rallies — here’s what to watch next

UnitedHealth (UNH) stock gains after Barclays target hike as Jan. 27 earnings loom
Next Story

UnitedHealth (UNH) stock gains after Barclays target hike as Jan. 27 earnings loom

Go toTop